ES2135353A1 - Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones. - Google Patents

Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.

Info

Publication number
ES2135353A1
ES2135353A1 ES09800625A ES9800625A ES2135353A1 ES 2135353 A1 ES2135353 A1 ES 2135353A1 ES 09800625 A ES09800625 A ES 09800625A ES 9800625 A ES9800625 A ES 9800625A ES 2135353 A1 ES2135353 A1 ES 2135353A1
Authority
ES
Spain
Prior art keywords
beta
estradiol
analogs
glucose
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09800625A
Other languages
English (en)
Other versions
ES2135353B1 (es
Inventor
Escoms Bernat Soria
Navajas Angel Nadal
Orts Cristina Ripoll
De Miguel Juan Manuel Rovira
Sanchez Etelvina Andreu
Ouahiba Laribi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Miguel Hernandez de Elche UMH
Original Assignee
Universidad Miguel Hernandez de Elche UMH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Miguel Hernandez de Elche UMH filed Critical Universidad Miguel Hernandez de Elche UMH
Priority to ES9800625A priority Critical patent/ES2135353B1/es
Priority to PCT/ES1998/000249 priority patent/WO1999048502A1/es
Publication of ES2135353A1 publication Critical patent/ES2135353A1/es
Application granted granted Critical
Publication of ES2135353B1 publication Critical patent/ES2135353B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Abstract

La Diabetes Mellitus es un desorden de la homeostasis de la glucosa, siendo una de sus características la disminución de la secreción de insulina inducida por glucosa. La insulina es una hormona peptídica sintetizada, almacenada y liberada por las células tipo B de los islotes de Langerhans del páncreas. La utilización de 17{b -estradiol, sus análogos y derivados en el tratamiento de la Diabetes Mellitus tiene su origen en los efectos de los estrógenos sobre los mecanismos de secreción de insulina. La adición de 17{b -estradiol, sus análogos y derivados potencia la secreción de insulina para concentraciones de glucosa por encima de 7mM, sin producir efectos en ausencia de glucosa o a concentraciones inferiores a la umbral (5-7 mM), por lo que evita el riesgo de hipoglucemias severas, la complicación más seria de los tratamientos antidiabéticos más utilizados.
ES9800625A 1998-03-24 1998-03-24 Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones. Expired - Fee Related ES2135353B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES9800625A ES2135353B1 (es) 1998-03-24 1998-03-24 Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.
PCT/ES1998/000249 WO1999048502A1 (es) 1998-03-24 1998-09-14 UTILIZACION DEL 17β-ESTRADIOL, SUS ANALOGOS Y DERIVADOS EN EL TRATAMIENTO DE LA DIABETES MELLITUS Y SUS MANIFESTACIONES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9800625A ES2135353B1 (es) 1998-03-24 1998-03-24 Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.

Publications (2)

Publication Number Publication Date
ES2135353A1 true ES2135353A1 (es) 1999-10-16
ES2135353B1 ES2135353B1 (es) 2000-08-16

Family

ID=8303212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9800625A Expired - Fee Related ES2135353B1 (es) 1998-03-24 1998-03-24 Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.

Country Status (2)

Country Link
ES (1) ES2135353B1 (es)
WO (1) WO1999048502A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US6998395B2 (en) * 2001-08-17 2006-02-14 University Of Pittsburg, Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
EP1358882A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JPWO2011007882A1 (ja) * 2009-07-16 2012-12-27 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARLETT, P.B. et al., "Estradiol and progesterone modulation of glucose uptake rates by peripheral tissues in diabetic C57BL/KsJ mice", 1989, Med. Sci. Res., 17 (8), paginas 387-389. Todo el documento, especialmente "Introduction". *
CROOK, D. et al., "Hormone replacement therapy with dydrogesterone and 17beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up", 1997, Br. J. Obstet. Gynaecol., 104 (3), paginas 298-304. Paginas 302 y 303: "Discussion". *
LEITER, E.H. et al., "The influence of genetic background on the expression of mutations at the diabetes locus in the mouse. IV. Male lethal syndrome in CBA/Lt mice", 1981, Diabetes, 30 (12), paginas 1035-1044. Pagina 1037, lineas 23-40; pagina 1043, lineas 18-22. *
PUAH, J.A. et al., "Insulinotropic effect of ovarian steroid hormones in streptozotocin diabetic female mice", 1985, Horm. Metab. Res., 17 (4), paginas 216-218. Todo el documento, especialmente, pagina 217: "Results & Discussion". *

Also Published As

Publication number Publication date
WO1999048502A1 (es) 1999-09-30
ES2135353B1 (es) 2000-08-16

Similar Documents

Publication Publication Date Title
NO20090846L (no) Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav
CA2373266A1 (en) Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
HUT68525A (en) Pharmaceutical compositions of prolonged delivery, containing peptides
WO1999043705A8 (en) N-terminally truncated glp-1 derivatives
AU2610899A (en) N-terminally modified glp-1 derivatives
Konturek Somatostatin and the gastrointestinal secretions
ATE193541T1 (de) Insulinotropes hormon
GR3021713T3 (en) The combination of growth hormone and insulin-like growth factor-i enhances growth
UY24893A1 (es) Combinaciones para diabetes de sulfonilurea glitazona
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
Sandler et al. Effective long‐term treatment of acromegaly with a long‐acting somatostatin analogue (SMS 201–995)
Fölsch et al. Effect of somatostatin on basal and stimulated pancreatic secretion in the rat
BR9810445A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e diguanida
IL146868A0 (en) A pharmaceutical composition containing an igf-i/igfbp-3 complex
ES2135353A1 (es) Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.
KR920700227A (ko) 초고활성 인체 인슐린 동족체
CA2113856A1 (en) Antidiabetic Agent
Efendić et al. Studies on the inhibitory effect of somatostatin on glucose induced insulin release in the isolated perfused rat pancreas
Efendić et al. Relative effects of somatostatin and two somatostatin analogues on the release of insulin, glucagon and growth hormone
AP2000001735A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
BR9810142A (pt) Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR199903072T2 (xx) Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi.
MARCO et al. Inhibition of intestinal glucagon-like immunoreactivity (GLI) secretion by somatostatin in man
Eng et al. Exendin-3 and-4 are insulin secretagogues

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991016

Kind code of ref document: A1

Effective date: 19991016

FD2A Announcement of lapse in spain

Effective date: 20180629